Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD). No liver injury has been observed with tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPK...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Toxicol Sci
Главные авторы: Woodhead, Jeffrey L., Brock, William J., Roth, Sharin E., Shoaf, Susan E., Brouwer, Kim L.R., Church, Rachel, Grammatopoulos, Tom N., Stiles, Linsey, Siler, Scott Q., Howell, Brett A., Mosedale, Merrie, Watkins, Paul B., Shoda, Lisl K.M.
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2017
Предметы:
Mechanisms of Tolvaptan-Induced Liver Injury
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216653/
https://ncbi.nlm.nih.gov/pubmed/27655350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/toxsci/kfw193
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы